Year: 2017
-
13 Dec 17 New Data Supporting Use Of Anagrelide To Treat Cancer
-
12 Dec 17 Appendix 3B amended
-
12 Dec 17 Change of Director’s Interest Notice
-
12 Dec 17 Appendix 3B
-
06 Dec 17 SUDA Licensee Submits Marketing Authorisation
-
29 Nov 17 Change of Company Name
-
28 Nov 17 Appointment of David Phillips as Advisor to the Board
-
28 Nov 17 Results of Meeting
-
28 Nov 17 AGM presentation
-
28 Nov 17 SUDA Acquires Novel Oro-Mucosal Anti-Cancer Agent